REGISTERED CHARITY NUMBER: 3272116 Tru5tees' Rert attd Audited FinAD¢fjal Ststements for the Year Ended 31 De¢ember 2025 for Drug Safety Researeh Trn$t
Dru¥ Safety Research Trust Cont¢nts of the Finan¢lal Statements for the Year Ended 31 Deeember 2025 Page Reference and Admithlstrntlve Details Trustees. Report State¢t of Tru5tee5' Responslbllltl¢$ 10 Rewbrt of tbe IndependeAt Audltors 11 to 14 Statement of Flnancl#l Actlvltles 15 Statemertt of Firtaneial Position 16 Statement of Cash FIDY4$ 17 Notes to the Si*tement of Cash Flows 18 Notes to the Flnan¢lal stateents 19 to 29 Detalled Statement of Flnanelal AetR)4ties 30 to 31
Drug Safety Research Trust Reference and Admintstratlve Detsiis for the Yexr Ended 31 December 2025 TRUSTEES Prof¢55or Kenneth Ross Paterson MB ChB FRCP FFPM FBPhS (Chainnalll Prof¢550r John Can1 QHP BS¢ MD FRCP FESC FACC FAHA FCGC CStJ Profe550r Martin Ves5¢y CBE MD FRCP FRCOG FRCGP FFPH Fmcdsci FRS Piofessor Allan Hunter Young MB, ChB, MPhil, PhD, FRCPC, FRCPsych PTofe5sor Isla Ma¢kenzie MB ChB PhD PGC¢rtMcdEd FRCP Edin FBPhS FBIHS DIRECTOR Dr Linda Harllwk M.Pharn4 M.Epi. Ph¢L MBA lappoillted 22 April 20251 PRINCIPAL ADDRESS Drllg Safety Research Unit Bur51edon Hall Bur51edon Lane Bur51edon Southampton S031 IAA REGISTERED CHARrrY NUMBER 327206 INDEPENDENT AUDITORS Cartwrights Chartered Accountants and Bu5ines5 Advisors Statutory Auditor Regency House 33 Wood Street Barnet Hertfordshire EN5 4BE PROFESSIONAL ADVISERS Solicitors Patis Smith LLP Number l LonÉton Road Southampton S015 2AE Jnv¢stment Managers Rathbones lThvcstm¢nt Manageent Limited 30 CJr¢%ham Strcet London EC2V 7QN PRll¥CIPAL BANKERS Lloyd5 Bank plc 92-94 Above Bar St SouthaMOn S014 7DT
Drug Safety Research Trust Tru$t¢e$' Report for the Year Ended 31 December 2025 The Trnstees present their re}rt with tbe fillancial sratements of the ckniry for the year ended 31 December 2025. The Trustees have adopied the provisions of Accounting and Reporting by Charities.. Siatemellt of Recommendeij Pracute applicable to charities preparing their accounts in accordance with the Financial Reponing Standard applicable in the UK and Republic of Ireland (FRS 102) (effective l January 2019}. Objeetives and aims Established in 1981. the Drug Safety Research Unit IDSRUI mission is to protect public health by studying the use alld adverse effects of medicines and vaccities in real-world clinical use, working to tbe highest possible seientifie stattdardg. All of our work seeks to facilitate the healtb and wellbeing of pIentS by putting the interests of patients first and protectitlg people from the hazards of medicines. To achieve this mission. the DSRU ¢JtTer a range of observational studies to examine the safety of medicines, including new medicioes. new fomiulalions for existing medicines and when medicines are used for new indications or in new populations. or when safety issues or questions about the use, benefit-risk balance or effectiveness of medicines arise. In addition. the unil conducts utilisation studies for medicines and vac¢ines ¢0 enable underStandig the use and effects of pr(Nluds on the healthcare system and behaviours and responses of patients and healthcare professionals. The type of sdIeS offered include CPRD sdies, p)st-allthorisation s*f¢ty Studies (PASS) in primary and wondary care, registries (including for the Early Access to Medicines Sehtme, EAMS), European network studies, $ystem2ti¢ reviews, drng uttlition studies and benefjt-risk assessments. It also offers services with regards to the design and implementation additional risk minimisation measures and to monitor their effectiveness. In additio DSRU Seeks to contribute to the advancement of phannacovigilanee 2nd phamwoepidemÈology by conth]cting methodological research. leading or participating in natioTLa] aTLd international research network5 and scientific collaborative projects and by orgalllSing meetings and eonferences to explore and develop new methods and innovations in phaMCov1s][acC and pharnracoepidemiology. DSRU Consultancy provides advice on strategies. thdy designs and options for post-marketittg pharnJacovigilan¢e. pham)acoepidemiology. risk minimisatith) and risk management planning for large and small pharmaceutical companies. DSRU Educath"on & Training is phamia¢oepidemiology and risk managemenL leading European provider of training in pharn)a¢ovigilan¢£, OBJECTIVES AND ACTIVITIES ObjeetÉves and aims We continue to rnonitor developments in the UK relationship with the EU atLd make adjustments to our systems as appropriate to adthess relevallt i55ues arising froln these changes. The Director keeps in regular contact with the Regulatory Agencies #t our European colleagues to obtain infotmation in order io shape our strategy and policy, particularly on Matte relaied to the impact of Brexit o medicines regulations and me(Ji¢al research.
Drug Safety Research Trust Trustees. Rep)rt for tbe ye Ended 31 De¢tber 2025 OBJECTIVES AND AcfIvITIES Significant activities Rese#rch The DSRU continues to function as one of the leadillg Ullits in the field of monitoring and $thyIng the Safety of meth"cities both in the UK and iniernationally, as well as being a leading organisatiotL 111 teaching 22Jd training in these fields. Progress of the scientific work of the Unit was tISfaCtory throughout 2025 and intluded st authorisation fety studies (PASSI (many of which use Clinical Prdctice Research DataliTJk ICPRD) data). systematic reviews, dwg utili5ation projects and methodological research. In addition, our programme of activities has included collabating with a b102d range of doctors in England through Health Research Networks from dEffering specialities 8$ well as ¢ollaboratiog with colleagues in Europe. The policy to extend the range of scientific activities. as funding allows, will cottlinue. Applications for fimding frorn bodies including grant-givillg bodie$. pharntiCal companies and Europ¢an initiatiY¢s, e.g., the European Commission, will eontinu¢. The DSRU has a fornial collaborative partnership programme agreemen¢ wilh the NHS Business Services Authority to receive prescripiton data that are neccssary to conduet Modified Prescription-Event Monitoring studies to improve the understanding of the safety of new drugs cd in the general population. This pajthership has the support of the Dq)artm¢nt of H¢alth and senior staff at NHS Busin¢ss Services Authority. Sin¢¢ application for Section 251 exernptiots of the NHS 2006 Act became a requirement, th¢ Trll5t has applied annually to the Confidentiality Advisory Group (CAG} of the Health Research Authority for approval to use patient data without ¢owent. Edueatlo The DSRU provides advic¢, education and training in pharmacovigilance and related subjects and works to improve the methods used to study and understand the safety of medicit)es. As one of the mairt providers of training and education in pham)a¢oYigilan¢e in Europe, its activities include.. Providing a rdnge of training courses in phamia¢ovigilanc¢ and phann•¢o¢piderniology. The DSRU Currently provid¢s 12 courses per year, as well as a Postgraduate Certificate, Diploma and a Mastees degree in Pham]a¢ovigilance in co112boration with University of Portsmouth and Phatma¢eutical Medicine Specialty Trainin8 (PMSTI for doctors specialising in plkarmaceutital medicine in collaboration with the Faculty of Pharniaceutical Medicine. - Providing external training and education when required. - ASing national and internationd confeTence5 ill phaMjavigllan¢¢ and phamiaco¢pidemiology. - Providing postgtaduate teaching and research opporttmities at all l¢v¢ls. - Providing training in pharO¥lg]1ance and pharn)acoepid¢miology for phami¢Uti¢a1 physician5. - Supporttng training and s¢icntsfi¢ communications on the safety of medicines in the UK and intemaiionally. - Providing advice on tte[S related to the safety of medicines. - Producing newsletter5 and intetnet communications on matters to do with drug safety.
Drug S&f¢ty Rearch Trust Trustees, Report for the Year Ended 31 December 21125 OBJECTIVES AND ACTIVITIES Objectives When rquired, report5 the results of studies are sent to the Medicines and H¢alih¢2re Products Regulatory AuthOrty IMHRA) lan executive agency of the Department of Health) and to the Europe2n Medicines Agency IEMAI and other RegulOry Authotities itt Europe to assist them in their regulatory and monitoring 2Ctivilies of medi¢ines. The DSRU Sends reports of its Studies to Marketing Authorisation Holders of medicines and vaccines and also publishes fjndings of its work in scientific journals and al national and Internation conferences, newsletters and on it9 website. Attiwities The rnain objeetlVC5 of the Unit for the next year are.. - Continuing with the Core activities of The utkit such as SdieS on the safety and utilisations of vaccines and medicinal product5, benefit iisk assessments and risk minimisation activities. - Itllplement a new busitiess strategy forthe coming years. Trallsltion data analysis tools to keep up to date with the developments in the scientific world. To Stretth¢ft the organisational stsucture so the DSRU can fuifjl it8 mission. To have increased attention for the organisatiollal development so th¢ DSRU is a place wher¢ employees can d¢velop professionally and wher¢ they feel at home. Actively search for new business opportunities. To continue to ty io secure suffJ¢ient fiinding from different sources (public and private) to enable the ¢ontinuation of the charity's a¢tivities. - Changing to a n¢w platforn for data capture. Pvbllt benent Th¢ Trustees ¢onfirni that the Charity Cotllmission's 8eneral guidance on public benefit h&s been considered in relation to the ObltiveS of th¢ charity. The objectives, a¢tivities, perforniance and achievement sectton5 of this report clearly set out the activitie5 which the charity undertakes for public benefit. Th¢ Trustees confirtn that they have complied with thcir duty in Stion 4 of the Charities Act 2006 to have due regard to public benefits guidaTLce published by the Chariti¢5 CoTJUni5SiOll in deterniining the activities undertaken by the chaTity.
Drug S4(tty Research Trust Try5tees' Report for the Year Ended 31 De¢ember 2025 ACHIEVEMENTS AND PERFORNIANCE Charitable aetivitles The su¢¢essful annual submission and Subsequent approval and support of the Ethics and Confidentiality Committee of the Confidentiality Advisory Group ICAG) of the Health Research Authonty for Section 251 exemptioll vnder the NHS Act 2006 was achieved for tb¢ sixteenth-y¢ar running. The Certificate, Diploma and Masiers degree ID phannavI81[ttn¢e ill collaboration the University of Portsmouth Continued, with I15tud¢nts ¢nroll¢d at th¢ ¢nd of th¢ year. Seven scientific papers wer¢ published in mcdic21 literature. Four abstr&ct&lposler presentations on tbe results of studies were given by DSRU staff at national alld international medical and scientific Conferences. One Registry study, one Drug btilisation SdY and five CPRD studies w¢re eonwleied attd delivered during 2025. In addition, one interim report and two study progress reports were delivered. The DSRU has provided pharmacovigilance consultanw support to phamweutical companies when requested. Edu¢#tion and Prfrfesslonal Capablllty The educational training of staff has been maintained in¢luding eontinuin8professii)tJal development. Tfa¢hithg & Edueatio The Head of Epidemiology alhd Reseateh tAught students at the University of Hertfordshire on their Msc PharmacoYigiLance course. Ill addition, teaching and presenting at n&tional ond internatonal scielltific meetin8S continued by both the DirectOT and 5¢nior scieTktifi¢ staff ¢ttablittg th¢ s¢ienttfic profile of the Unit aTLd its work in public hea]th and drug safety to be maintained. Tralnlng Courses for Pharmaceutical Medicine Sptei#llty Tralnlng The DSRU continues to offer teaching courses in phaTmacoiigilan¢e, providing training on drug $ety module5 of Pharn)aceutacal Medieine Specialty Training {PMST), for phanna¢¢uti¢al phy$ician$ on behalf of the Faculty of Phamiaceutical Medicine, Royal College of Physicians. Partners and StAkeholders Uijiveisity of Portsmouth The DSRU is an affiliate department of the University tsf Portsmouth and collaborations on jotnt stlldentships and joint tr&inang continue. Regulatory Agencies Cli)se litths were maintained throughout the year with the Medicines and Healthcare product6 Regulatory Agency IMHRA} and the European mlCineS Agency IEMAI wilh regular reports i>ll safety issues submitted, contributing to the better understanding of the Safety of a number of important medicinal products. The DSRU 15 a member of the Europvdn Network of Centr¢s for Pharnvdcoepidemiology and Pharma¢ovigilance IENCePPI, a project led by the European Medicines Agency and developed in collaboration with European experts in the fields of pharniacoepidemiolo8y and pharniacovigilance. Senior staff of the DSRU regularly participate in meetin8s of the ENCePP network gFOUP. VAC4EU Th¢ DSRU is a member of VAC4EU which is a collaborative network of 28 member organisations acFOSS Europe which ¢onduct studies on the safety 9nd effects"veness of vaccines. The network i5 Id by Ptofes50r MiTiaTn StUTk¢nboom (the University of Utrecht in ihe Netherlattdsl. The DSRU is conductÈng one study on a COVID.19 vaccine and three sNdies on che RSV vaccine in Collabordtion with members of VAC4EU. The DSRU is using Clinical Practice Research Daialink {CPRDI, the leading resource in the UK of primary care clinical data io conduct these studies by Pfizer. white our collaborators are using databases in a nutthr of European countEtes.
Drug Sgfety Researth Trust Tru5tee5' Report for the Year EDded 31 DeCeber 2025 International $cielltific leadership collaboration The DSRU is leading aD Intetnational WOlg Group {IWG) for New Developments in PEwmacovigilance. Group it]cludes solne of the best ¢xpert5 in the world iti "$ field. The objective is tts identify aieas where contributions can be nde lo advance methods used in pham¢ovigilan¢e and phamia¢oepidemiology. Such developments include artificial intelligence llmchine learning, and the applicatitsn of geThetic knowledge in detecting and evaluatsng adverse drug react10115. The wo& has progEessed well attd the results of the first wod(stregm was pubhthed in 2025 with the result of the second workstteam due to be published in 2026. Investment performance The Trnstees are satisfied that the current investment approach of tbe Trust is consistent with its investment nee&, objectiv¢s and attitude to risk, whsch is to provide F4 balanced return on investment ill the rnediutll term with a i)derate risk of capital lo&s. The retllm on investtnent incr&ed from £66.907 to £92,335 ill 2025. FINANCIAL REVIEW Flnanclal po$ltlon The ac¢ounls have been prepared in accordance with the accounting policies set out in note I to the ¥¢ounts and Comply with the ¢harity's Twst Deed, th¢ Charities A¢1 5993 and the Stst¢m¢nt of R¢comm¢nded Practice, 'A¢¢ouThting and ReportinÉ by Charities" issued in Mar¢h 2005. The Statement of Finaneial Activities for the year is set out on page 15 to thc5e financial statements. Prineipal funding $oure Principal funding 50ur¢es come from dotjations r¢ceiv¢d from pharmaeeutical companies aDd other organisations in OTdeT tt> caTry Out charitable 2Ctivilies. Whilst some costs are provided ill advance by funders, the entitlement to income only arises when 5eparat¢ly identifiable stsges of the projects are completed. The charity monitors the progress of the projects closely and only intludes the income and associated costs as and when these conditions are md. Thi5 treatrn¢nt meets the charitys accounting policy regarding incoming resource5 as set out under accounting policy 1.2 in the notes to the financial $tatements. StatTJng ¢osts {gross salaries plu5 employers, national insurance) in 2025 were £1.461.821 compared tt> £1.469.838 i 2024. Salarie$ still forni the major part of the charity's expenses due to ihe specialist nature of employees, e.g.. medical doctors &nd 5cientist5 lleeded to carry out the resear¢h activities. Ttsul wage ¢osis including naiion31 insuraE)ce and pensiort contributions therefore remain the highest expendittwe for the Tn1 on a year-by-year basis. The Chaiman of Trustees and Director maintained ¢lose s¢ntY of incoming resources and expendittwe during the year and kept the Board infornied maintaining the same level of financial governaDce as in previous years. Investment polley and objeetlves Th¢ Trust has undertaken investment in equitEes and bond5 Ilwough Rathbortes {incory>otating Inve5te¢ Wealth & Investment Ltd). In order to mOE)itor the investtn¢nt portfolio perfot]nance. two Trustees and the Director act as a sub-conunittee. This group, on behalf of the Board of Tru5te¢s, deals with all matters relatiTh8 to the investment portfolio and tneets Wlth r¢pT¢sentativ¢s of Rathbon¢s litt¢oJporating Investec Wealth & Investment Ltd) at appropriate intetvals. It 15 the policy of the B()ard of Trustees that no ittvestments in the phomaceutical, armaments or tobacco industrie5 should be undertaken. Annually fro a anageMent perspe¢ts"ve all other fwids not immediately required from month to month for the nortnal Tunning of ihe DSRU we routinely invested in fixed tern) deposit accounts to maximise return when¢Y¢r P0$5ible. The Ttust's slntegy to invest whenev¢r possible io offset for leaner years when donations are reduc¢L will b¢ mainlailled.
Drug Safety Research Trust Trustees, Report for the Year Ended 31 December 21125 FINANCIAL REVIEW Re$erves poIiey It is the w>liey of the charity to maintain wjrestricted fills, w.Ch ale the free reserves of the Charity. This provides sufficient funds to cover the eost of ongoing studies, managcment and administration Costs. Cottsidering expected fluctwtions of futyre in¢ome, the fancial res¢rves are ncccssary to maintain the future stability and viabiliry of the DSRU. These reseryes will be used when and if fid5 bccome too low to coycr noal day tt> day activities. In these difficult economic timcs, the Trust is rcaping the benefit of the prudent finatscial policy in the last decade. This approach will be ¢ontinucd in lin¢ with Ilcvclopm¢nts in thc ¢xt¢mal econorDie envÈroument. A55et eover for funds An analysi5 of the assets atttibutable to the various funds des¢ribed is set out in the notes to th¢s¢ financial statenLents. Tbese assets are sutTicient to meet the charity's obligations on a fund-by-thnd basis. Going ¢oncerD The Trustees CODsider the fjnancial. operatill8 alld other tisk factots when assessing whether there is any signifi¢ant doubt over the Trust's ¥4bility to eontlnue as a going concem. Dllring its 40 plu5 years. the Trust ha5 e5¢ablished and followed a policy designed to ensure that, in th¢ highly unlikely event of a significant dTOP In income. it ha5 sufficient cash and CAsh equivalent reserves to enable it to wntinue its ¢harit2ble activities for & period of at least 2 y¢ars. The TnEStees have considered the level of funds held and the expected level of income and eKPtnditure for 12 months from authorisitss th¢s¢ fin3n¢tal $tatem¢nts. The budgeted incotne and expenditure is sulTicient with the level of reserves for the charity to be able to continue &s a going concern. Since BrexiL theTe has bttn some uncertainty over the currettt regulatory environment and the impact this may have on the Trust's fullding. The Ttust is actively moniioritig and planning for any ¢han8e$, including repositioning itself to illciease th¢ numbei of studies b¢ingperfonn¢d in th¢ UK. Because of the healthy level of "free reserves" and th¢ operational steps taken to ty 2nd ensure that the Trt remaitts at the forefront of monitorillg and research in ihe field of pharmacovigilance and phanllacoepidetniology. the TTU5tees do not believe ihere is any such doubt and th¢r¢foTe b¢li¢ve it is appropriate to use the going concetn basis of prepardtion in the8¢ fillan¢ial s(at¢m¢nis. FUTURE PLANS Due to the new regulatory environment after Brexit the overall business strategy of the Unit has been reviewed and a new business Strategy has been developed and is being implem¢nt¢d. The Unit will Continue io conduct a broad range of studi¢$ to address safety questions, including observatio1 studies using bespoke data colledion. pharniacoepi(lemiological studies using already existing data sourcE5 and a Tange of different stLY designs, such as drug and vaccine utilisation studies, meta-analyses, SYStentiC review5, benefit-risk evaluations. Other 8ttY meihods to understand drugs and va¢¢ines safety, effectiveness use and utilR5ation. The DSRU will ltrdd or participate in national and international collaborative projects that aiTn to improve the methods and advan¢e the science of studying the safety of medicines. The DSRU wryll further develop its scientifi¢ tommunications programme to infomi the both the medicavseientific conllnunitics aTLd the publi¢ alx)ut important phaMa¢ovi1att¢e issues. The Unit will further develap its methods and capabilities in evidence-ba5ed phaTmacovigilan¢e and risk management and maintain its place as a leading Unit providing advice, trailling and education in phamiacovigilance and drug safery.
Drug Safety Rese3rch Trust Trustees, Report for the Year Ended 31 Decembtr 2025 STRUCTURE, GOVERNANCE AND MANAGEMENT Governing document The Trust is governed by a chatitable Ttusi Deed esiaiTrlished on 23 July 1986 with a Board of TTU5t¢es five in numb¢r. The Mission of the TTU5t iemain5 to tslI0r. SdY and communicate the safety of medicines indep¢nd¢nt from both Govenunent and industry. The TtU5t by way of its operational unit, the Drug Safety Research Unit IDSRU), ndertakes all forms of 5tudie5 and evaluations on the safety of medicines. The DSRU provides advice, training and education in phannacovigilance and reLated subjects and works io improve the methods used to SdY and understand the safety of medicines. As an illdependent registered medical chariry, its aim is to achieve the highest possible s¢ientific and ¢thicai standard$ by putting the interests of patients first and lo work with integrity and faim¢ss with all partners. Reeruitillent and appointment of lleiv trustees As a charity specialising drug safety. the TnteeS are identified for their expettise in areas which in¢lud¢ thg regulation, epidemiology and medical statistics, experimental medicine and plrn¢VigIlan¢e. Once 8ptx>inted, th¢ Trust ensure5 that any trdining r4uired by the Tnre¢S is provided to enable them to fulfil their rol¢. Trustees of the charity The Tnle£S acknowledge their re5ponsibililies as set out on the statement of Tjusiees responsibiliiies. Th¢ Trustees wkn have servcd thiring the year and sinee the year end were as follows.. Professor Kenneth Ross Paterson MB ChB FRCP FFPM FBPhS (chaimll) Professor John Camm MD. Fmedsci, FRCP(L,E&G), FESC, FACC, FAHA, FEHRA, FHRS, FBCS, FBHRS, FAL4,CStJ Professor Martin Vessey CBE MD FRCP FRCOG FRCGP FFPH FM¢dS¢i FRS Professor Allan Hunter Young MB, ChB, MPhil, PhD, FRCPC, FRCPsychP Proftssor Isla M&ckenzie MB ChB PhD PGCertMedEd FRCP Edin FBPhS FBIHS There have been no changes to the Trustees in the year nor to the date of sigtiing of the5¢ financial statements. Or¥y4nia*iion#l strnere The TtU5t employs a DIrtOr, assisted by Scientific, professional and administrative staff to conduct its day-to4iay activities. ensuring that the Charity's objectives are implemented. The Trust also r¢tains the services of appropriate advisers and consultants depending upon the nature of the tssks required. During 2025 the average number of staff employed for the year was 26. In addition, 11 consultants were engaged, to advise and assist with additiOTLal medi¢aVresear¢h inpu¢ IT and data protection, PRlmarketin8, planning matters, business strategy and prof¢s5ional development. Induetion and tralnlng of new trustees Induction is tailored to meet the needs of any new Tn]stee and will be detemiitted based on their own knowledge and exptrience. Whete neLessary, tsxining is provided on charity, governance and financial matters. Key managemettt rernulleratloll Th¢ Trustees, in conjunction with the Director where appropriate, are responsibl¢ for setting the pay and remuneration of k¢y tnanagement.
Drng Safety Research Trust Truste¢s' Report for the Year Ended 31 December 2025 STRUCTURE, GOVERNANCE AND TrL4NAGEMENr Risk management The Tntstees have a thEty to idet)tify alld review the risks to wbich the charity is exposed and to ensur¢ appropriate Controls are in place t(p provide reasonable assllrance against fraud and error. The Trusiees exaniine the major strategic, busines5 a[ operational risks and confinn that systems ar¢ established to enable regular retx)rts to be produced, so that necessary steps can be taken to control or lessen these risks. The variabiliiy of the funding of the Trust made it necessary to put in place processes io ensure that staff felt secure and motivated. A Disaster Re¢overy Pian for the DSRU ha5 been designed aThd eompleteiL The plan is secwed in off-site storage ithin a data safe. Approved by older of the board of trllstees on............. . and signed on its behalf by.. Professor K R Pat¢rson MB ChB FRCP FFPM- Trustee
Drug Safety Research Trllst Stateettt of Tru5tees' Responslbi]ities for th¢ Y¢ar Ended 31 Decejnber 2025 The truste¢s are r¢sponsibl¢ for pr¢paring the Trustees, Report and th¢ finawial stal¢m¢nls in accordance with applicable law and United Kingdom Awountlllg St&tthrds (United Kingdom G¢n¢rally Acc¢pt¢d ACConting Practice) including Financial Reportittg Standard 102 "The FinarLcial Rq)orting Standard applicable in the UK at Republic of Ireland". C1]ty law r¢wires tbe trustees to prepare fillancial ststements for each f]nancial year. Under that law, th¢ tNst¢¢s have elect¢d to prepare the fancIal statements in accordance with United Kingdom G¢nerdlly A¢¢¢pted A¢¢ounting Practice {United Kingdom AccountiiL8 Standard5 and applicable law). Under charity law the trustee5 must not approve the filncIal statement5 unles5 they are satisfied that they give 2 true alld fair view of the state of affairs of the charity and of the Encolg re50urce5 and application of resources. illcluding the incoille and expenditure, of the chatity for that period. In ptq)aTitEg those financial statemellt5, the trustees are requited to select suitable accounting policies and th¢n apply Iheth collsistently. obsenre the tnethods and principles in the Chariiies SORP,. make judgetnents and estimates that are reasonable and pn¢t. state whether applicable a¢¢ounting standards have been followed, subject to any material departtu¢s disclosed and explained in the financial statemenis,. prepare the financial statements on the going ¢on¢ern basis ull1¢58 It is inappropriate to presume that the charity will continue in business. The tn]stees ale responsible for keeping proper aceounling records which disclose with reasonabl¢ a¢¢urd¢y at any time the fEnancial position of the chatity and to enable them to ellsiire that the financial statements c<)mply with th¢ Charities Act 2011 and The Charity (Accounts and Reports) Regulations 2008. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. -1
Report of the Independent Auditors to the Trustee5 of Drug Safety ReseY4rch Trust Oplnion We have audited the fUn¢la1 statements of Drn8 Safety Research Tnt (th¢ '¢harityl) for the year ellded 31 December 2025 which ¢ompris¢ the Staternellt of Financial Activities, the Slaiemenl of Financial PosÉtion, the Statement of Cash Flows and llotes to the f]n2ncial statcments. itkcluding a sunllll2ry of significant accounting policies. Th¢ fuwicial r¢porting framework that has been applied in their preparation is applicable law al United Kmgdom Accounting Standards {Ullited Kin8dorn Generally A¢¢epled Accounting Prdcticel, including Fillancial Reporting Standard 102'Th¢ Finawial ReportiEJ8 Standard applicable in the UK and Republic of ITelaNI'. Ill our opinion the financial statem¢nts.' give a t and fair vt¢w of th¢ State of the charity'5 affairs as ai 31 December 2025 and of its inciTrmiDg resourtes and application of resources, forthe year then ended,. have been properly prepared in accordance with United Kingdom Generally AccepÉ¢d Auting PractÈ¢e. in¢luding Financial Rep)rting Stalldard 102 'Th¢ Financial ReportitEg Standard applicabl¢ in the UK atHI Republic of Ireland and have been prepared in accordance with the requirements of the Charities Act 2011. Bas1$ for oplnion We condu¢d our audit in accordance with Illtemational Standard5 on Auditing (UK) {ISAs (UK)) and appli¢abl¢ law. Our responsibilities under those sttMlar(ts are further described in the Auditors, iesponsibilities for the audit of the financial statements sedion of ollr POrt. We are independent of the charity in &ccordattc¢ with the ¢thicAI requirements that are relevant to ow audit of the financial 5tatemetsts in the UK including th¢ FRC'S Ethical Standard, and we have fuifjlled our other ethical responsibilities in accordance th¢se requirements. We b¢lieve that the auth"t evidence we have obtained is $utTicient and appropriate to provtde a basis for our opinion, Conelusffions rei#t5ng to going Concern In audiling the financial statemen we have concluded that the trustees, use of ttle going Concern basis of a¢¢ounting in the preparation of the financial statements is appropriate. Based on the WO we have perfOrn(l we have not identified any terIal un¢ert&inti¢s lati1]s to events or conditions that, individually or collectively, may cast significant doubt on the charity's ability to continue as a goin8 concern for a period of ai least twelve months from whell the financial staÉtments are authorised for issue. Our responsibilities and the responsibilities of the trustees with respect to going con¢em are d¢s¢ribed in the relevant s¢¢ti0115 of this report. Other infortThation The trustee5 arc F¢5ponsible for the oth¢r inf0mtiOn. The Oth inf0mtion COFnprises the inf0mtIOn in¢lud¢d in the Annual Report, other than the financial statements and our Report of the Independent Auditors thereon. Our opinion on the finan¢ial statements does not cover the other Enfommtion and. except to the extent othen¥ise explicitly stated in our repo¢ we do not express any forni of &ssurance conclusion thereon. tn connection with our audit of the financial statem¢nts, our responsibility is to ad the other infonnation and, in doing 50, ronsi&r whtthtr the other informatiorj is materially inconsistent with the fJnanci&l statelnents or our knowledge obtained in th¢ audit or othenvi5e appears to be maierially misstaied. If we identify such material incoiLSl5ten¢ies or appartnt material mi5Statements, we are required to d¢temiin¢ whether this gives rise to a material In15Stat¢Trent in the fittancial statemcnts themselves. If, based on the work we have perforn)td, we conclude that there 15 a rtlaterial misstaiemeni of this other infortnatioN we are required to repott that fact. We have nothillg to report in this regar Matter5 on whi¢h we Are required to report by ¢x¢eptioD We have nothing to report in respect of the following matters where the Cltsrities {Accounts and Reports) Reglllations 2008 requires us to tH)Ort to you if, in our opinion.. tILe information given in ihe Iruslees R¢port is incon5iStent in aDy material respeci with the fjnancial slatements: or sufficient *c¢ountittg records have not be¢n kept. or tILe finallciaj statements are not in agreement with th¢ accouutiIi8 records and reNtrns: or we have not received the information and ¢xplaDatioll$ we requÈre for our audil.
Report of the IndepeMd¢nt Auditors to the Tru$tee$ of Drug Safety Research Trust Responsibilities of trustees As explained more fully in the Statement of TrusÉee5' Responsibilities, the trL]slees are responsible for the preparation of the financial ststements which give a tnte and fair view, and for such internal control as the tjustees detem)ine is necessary to enable the preparation of flnancial statements that arc frcc from material mtsstatemenl, whether due to fraud or ¢rror. In preparing the fLDaneial statements, the trustees are respoajsible for assessing the charity's ability to continue as & going concern, disclosing, as applicable, matters rclatcd to going concern and using the going Concern basis of accounting unless the trLtstees either intend to liquidate the charity or to cease opcrations, or havt no rcali$tic alternative but to do so. -12-
Report of tbe Independent Auditors to th¢ Trustees of Drug Safety Research Trust Our responsibilities for the audit of the fmancial Statements We have been apBx)inted as auditors under Section 144 of the Cknitics Act 2011 and report in a¢cordance with th¢ Art and relevant regulations made or having effect thereunder. Our objectives are to obtain reasoDable assurance about whether the fUMla1 sratements as a whol¢ are free from material misstatemen¢ whether due to fraud or error, alld to l5sue a Report of the Independent Auditors that ClUdeS our opinion. Rezsonabl¢ as8urance is a high level of &ssurance. but is TEOt a guarantee That an audit conducted in accordance with ISAS IUKI will always detect a material misstatemellÉ when it exists. Misstatements can arise from frdud or error and arc consid¢red material if, individually or in the Aggregaie, they could reasonably be ¢xpect¢d to influen¢e the economic dccisions of u5crs tak¢n on the b&si$ of these financial statements. The extent to which ourpro¢¢dvres ar¢ pable of d¢t¢ctillg irregularities, fftncluding fydud is detail below.. We ensured that the ¢nga8ement tealn eollectively had the appropriate competence. capabilities 2nd skills to identify or recognise non-¢ompliance with applicable laws and regulations. and that th¢y remained alert to illstallces of non-complion¢e throughout th¢ avdit. r approach to identifyllig and assessing the risks of material missiatement in respect of irreities, including fraud and non-¢ompliance with laws and regulations. was as follows.. - ba%d on our understanding of the chlty and sector. and through discussions with twstees and key management, we identified ally sp¢¢ifi¢ laws and regulation5 which we consided may have a direct material effect on the financial stalemet)ts or the operation5 of the charity, includiDg th¢ SORP 2015, Comp2nies Aci 2006, t*LKation legislation Rnd data protection, &nti-bribery. eTnploymenL environmental attd health and safery Itgislation,. and we a&ses5ed the extellt of con]pliance with these laws and regulations through making enquiri&% of management and inspecting le8al correspondence. We assessed the sU¢ptibl]Ity of the charÉty'$ finantjAI statemettts to m&terial mi&thtem¢nL including obtaining an understanding of how ftaud might o¢¢ur, by.. - nking enquirie5 of Tnanagemtnt as to where they considered th¢r¢ w&8 susceptibility to fraud. their knowledge of actual, 5USP¢Cted and alleged fraud. and - eonsideTill8 tht internal controls in place to mitigate risks of fraud and non-¢(Fmpliance with laws and regulations. To addtess the risk of fraud through management bias and ovetTide of contro15, we.. - P¢TfcTmed analytical procedures to identify any unusual or unexpected relationships. - tested journal entri¢s, particularly focused around the Ytr-end, to identify unusual tran5aciiotts', a55e5sed whether judgements and assumptlODS made in deterniiniTrg the accounting estimates in the notes to the finan¢i&l statements were indi¢aiiv¢ of potential bias.. and - invesiigated the Tational¢ behind significant or unusual transactions. In response to the risk of irregulari¢i¢s and non-complianee with laws and regulation& we designed pr(dureS which included, but were not limited to.. - agreeing finat)cial statement disc105ures to underlying supporting documet)ÉatioJ; - reading the minutes of meetings of those Charg with goveanlY., - enquiring of managetnent as to actual and potential litigation and clitims: and - reviewing ¢orrespondenoe with HMRC, relevant regulators and the chaTiry'S legai advisors. There are illhent limitations in the audit proctdutes d¢5CTibed above. We are less likely to become aware of instances of ni>n-¢omplianct with law5 atld regulations that ate not closely Telaled to events and transactions reflected in the finan¢ial stat¢ments. Also. the risk of not detecting a mat¢iial misstatemettt due to fraud is higher than the risk of tjot deteciing on¢ resuitillg frorn error, as fraud may invtslve dehbetate ¢on¢ealment by, for example, forgery or intentional misrepresentatLons. or through cotiusion. A further description of OUT r¢5pon5ibilitie5 foi the audit of the financial statements is located on the Financial Reporting Coullcil'5 website at www.frc.org.uklauditorsresponsibilities. This description forms part of our Report of th¢ Independent Auditor5. -13-
Report of the Independent Auditor5 to the Trustees of Drug Safety Research Trst Us¢ of report This r¢port is made sol¢ly to the charity's ttustees. &$ a body, in accordallce with Part 4 of th¢ Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertak¢ll so that we might stale to the ¢lwitys trnstees those matters we are required to stat¢ to them in an auditor5. rtport alld for no other pUOse. To tbe fi]Ilest extent perniitted by law, we do not accq)t or assume responsibility io ayOne other than the charity and the charity'5 tnte¢S as a body, for our audit work, for tbis repo¢ or for the opillions we have f0rlli. cartryi8ts Chartered Aecoulltants and Bu5illess Advi50ts statory Auditor Regency House 33 Wood Street Bamet Hertfordshire EN5 4BE Date.. zaz6 Andrew Hill FCA {Senior ststOry Auditor) for and on behalf of Cartwrights -14-
Drug Safety Research Trust Staternent •f Fitianel41 Aetlvltles for the YeAr Ended 31 December 202S 31112125 Tot41 funds 31112124 Total fuDds Unrestricted fund$ Restrlcted ruDd Notes INCO14 ALW ENDOITrTrqENTS FROM Donations 41ttd l¢gaLies 958,187 958.187 704,584 Inves¢ment income Oth¢r income 257,075 35,665 257.075 35.665 234.799 233,762 Tot81 1250,927 1,250,927 1,173,145 EXPENDITURE ON Raising funds 24,341 24,341 24,633 CkArltable acthdtles Direct Charitabl¢ Expenditure 1,433,979 18,780 1,452.759 1,706,844 Oth¢r 765,871 765,871 746,924 Total 2,224,191 18,780 2,242,971 2,478.401 Net gains on investments 209,474 209,474 113,703 NET INCOMEIIEXPENDrruRE) (763.790) (18,780) (782,570) (1,191,553) RECONCILIATION OF FUNDS Total ndS brought forward 6.866,214 415,500 7,281,714 8,473,267 TOTAL FUNDS CAIiBJED FORWARD 6,102,424 396.720 6.499.144 7,281,714 The note5 form part of these financial statements -15-
Drug Safety Research Trust St4tem¢nt of FinAnciAI Positiom 31 December 2025 31112125 Total funds 31112124 Total funds Unrestrlcted fund5 RestrieÉed fund Notes FIXED ASSETS TatTrgible assets Ye5¢nlts 67.832 4,220,406 396,720 464,552 4,220,406 459,704 4,311.066 12 4.288.238 396.720 4,684,958 4.770,770 CURRENT ASSETS Debtors Cash at b&nk 13 323,617 1.564.875 323,617 1,564,875 500,4(X) 2,091,721 1.888,492 1.888,492 2,592,121 CREDITORS Amounts falling due withÈn one year 14 (74.306) {74,306) (81,177) NET CURRENT ASSETS 1.814.186 1.814,186 2,510,944 TOTAL ASSETS LESS CURRENT LIABILITIES 6,102,424 396.720 6,499,144 7,281,714 NET ASSETS 6,102,424 396,720 6,499,144 7,281,714 FUNDS Unrestricted funds R¢stri¢t¢d fithds 15 6.102,424 396,720 6,866,214 415,500 TOTAL FUNDS 6.499,144 7,281,714 The financial staiements were approved by the Board of Tnte¢S and authorised for issue . and were signed on its behalf by.. on K R Paterson MB ChB FRCP FFPM- TrL]Stee Th¢ llot¢s f<)nn part of th¢se finan¢ial ststements -16-
Drug Safety Research Trust Statemellt of Cash Flows for tbe Year End¢d 31 Deceer 2025 31112125 31112124 Notes Cash flows from operating a¢tivitie5 Cash generated from operations 1925.043) (902,4201 Net cash used in operatillg activitie5 1925.043) 1902,420} Cash flows fro investing #ctivitie$ Purchase of tangible fix assets Purchase of fixed asset investtnents Sale of tangible fLxed assets Sale of fixed asset illvestments Interest received Dividends received (45,927) 1199.866) (12,451) 1130,535) 1,109 113,703 126,(A3 66,907 500.000 51.656 92.335 Net cash provided by investing activities 398.197 IrfA,776 Change in cash and cash equivalettt$ irt the rcportlng period Cash and e2sb equlvalents at th¢ beglnnlng of the reporting perIod {526,846) 1737.644) 11)91,721 2,829,365 C#sh and eash equlv8lents At the eDd of the reporti% period 1,564.875 2,091,721 The noies forni part of these fin&ncial 5taternents -17-
Dg Safety Research Trust Notes to the Statement of Cash Flows for the Year Ended 31 December 2025 RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES 31112125 31112124 Net expendlture for the reportlDg period la$ per the Stst¢m¢nt of FiDaThcial Activities) Adjustments for: D¢preciation ¢harges Oain on investments Loss on disposal of fixed assets Ittt¢r¢st received Dividends received Decrease in debtors Decrease in creditors (782.570) (1.191,553) 38,508 1209,4741 2,572 151,6561 (92,335) 176.783 {6.8711 31,669 {227.4061 {126,0431 (66,907) 711.557 (33.7371 Nel cash used in operations {925,043) {902,420) ANALYSIS OF CHANGES IN NET FUNDS At 111125 Ca$h fiow At 31112125 Net cash Cash at bank 2,091,721 1526,846) 1,564,875 2,091.721 1526,846> ,564,875 Total 2,091,721 1526,846} 1,564,875 The notes fomi part of these financial statements -18-
Drug Safety Research Trust Notes to the Fknancixl Stitements for the Year Ended 31 December 2025 ACCOUNTING POLICIES Basis of prep4riDg tbe fillanelal statemeDts The f]nancial statements of the chariry. whicb is a public benefit entity urAder FRS 102, have been prepated i accoidanee with the Chatities SORP (FRS 102) 'Accounting and Reporting by Charities-. Statement of Recommended Ptaetiee applicable io clmrities prepartng their accounts in a¢cordallce with the Financial Reporting Standard applicable in the UK and Repubhc of Ireland IFRS 102) (¢ffective l Jalluary 2019),, Financial Reporting Standard 102 'The Financial Reporting Standard applicable ill the UK and Republic 0£ Irelalld, and the Charities Act 2011. The fancial staments have be¢ll prepared under the histotical c05t convention. with the exttption of investments which are included at market value, as odified by the revaluation of certain assets. Going concern These ftnancial statemenis are prepared on the going concern basis. The trustees have a reasonable expectation that the charity will continue in operational existence for the foreseeable tre. The validity of thi5 8SSUtnption depends on the continuing surylus in free resetves. If the ¢hartry were lltiable to continue in exL5tence for the foreseeable thture. adjusiments would be necessary to reduce the balance sheet values of assets to their recoverable amounts and to reclassify fixed assets as current assets. Critit#l eeoumtillg judgements and key sources of estImatl& un¢ertalnty Judgement5 and estimates are continually evaluated and are based on historical experience and other factors. including expectatiolls of fvture events that are believed to be reasonable under the circutnStatLce5. ritical accountin estitnates and assum lions The charity makes estimates and assumpliotts concerning the fijture. The resultin8 accounting ¢stimat¢s wilL by definitton, seldom equal ihe related actual reslllÉs. Propety, plant and equipment tat)gible fixed assets are deprcciated over their useful lives taking into accounts residual value, where appropriate. The actual IEves of the assets atMI residual values are assessed onrtually and may vary depetsdittg ott a sjwnber of factors. Residual value a5se5sments Gonsider issu¢s su¢h as th¢ remaining life of the asset and projected disposal values. Re¢ognItio of income - income is recognised when receipt is probable and when the amount Can be measured liably. At the end of the financial y&qr all ongoing studies are reviewed and a¢¢rLd income ests"mated from th¢ available inf0mtIOn, based on the fvlfilment of the sttmly coDditiOll5 andlor mil¢sion¢s. Income All incoThe is T¢¢ognised in the Statemeni of Financial ActÉYities onc¢ the charity has entitlement to the fids. it is probabl¢ that the incotne will be received and the amount can be measured reliably. Foi donations to be re¢ognised the charity will have be¢n notified of the amounis and the sdtlement date in wtiling. If there are conditions attached to the donation and this requires a level of perf0mll¢e before ¢TLtitlement Can be obtained thet) incomc is dcfcrrcd until those condilioll$ are fully met or The fvlfilment of Ih05e conditions is within the control of the Charity at)d it 1$ probable that they will be fulfilled. Jnvestment income is eamed through holding assets for investment putposes such as shares. It includes dividends, interesi and unr¢alis¢d gains or losses on shares held Where it is ttot practicable lo identify investmeni management ¢osrs in¢urred within a scheme with reastsnt4ble accuracy ihe investment income is reported net of these costs. It is included when the amount can be measured reliably. Inierest income is recosnis¢d using th¢ eff¢dive int¢re$t method and dividend incotne is recognised as the charity's right to receive payment is estoblishe -19- continued..
Drug Safety Research Trust Not¢$ to the FinAn¢ial Statements- ¢ontinu¢d for the Year Ended 31 Deeember 2025 ACCOUIYTING POLICIES- continued Other income represents man2gement fees charged 2nd donations received from the Trust's Colt¢led trading entity, DSRU Education and Resear¢h Limited. Management fees are included when charged atsd donatLOIiS when received. Due to the cotllJe¢led tsare of this entity, donation income is re¢orded within other income rather than within doltiOnS and legacy income in the Siatemettt of Financial Activities. DebtQTS ar¢ recognised when the charity is legaily entitled to the income after ooy perfornan¢e conditions have been mel, the amount can be measured reliably and it is probable that the income will be received. Expettditure Liabilities are re¢ogThised as expendire as sTh)n as there is a legal or cothsttNciive obligation committing the charity Its that expendiwle, it is probable that a transfer of economi¢ benefits wll be required in settlement and the amouni of ihe obligation can be measured reliably, Expendiwre is accounted for on an aCfflTals basis and has been classified under headings that aggregate all cost related to the Category. Where costs cannot be directly attributed to particular headings they have been allocat¢d to activities on a basis consistent with the use of resources. Ralsing funds Cost5 of raising fLmds represent investment manager costs incurred in dealing with the listed investment portfolio Charitable attivities Expenditure on chltable actiwities includes the dii¢¢t cost5 OtcaTrying out and performing the studics and evaluations of ]nedicines in order to meet the chatity's objectives and all. Allocation aDd apportionment of eosts Support costs are those that a5Sl5t the work of the charity but do not directly represent charitable activities and include oflice costs. governance costs. adTnini5trative payroll cost5. They are incurred directly in support of expenditure on the object5 of the charity. Where support costs cannot be directly attributed to particular headings they have been allocated to cost of T&15ing [1d5 aTJd expenditure on charitable actiTritie5 on a basis consistent with use of the resources. Tangible fixed a55ets Tangible fixed assets other than freehold land are Stated at cost less depreci2tion. Depreciation i5 provided at rates calculated to write off the cost less estimated ressdual value of each asset over its expected eful life. as follow.. Freehold land Not depreciated Freehold buildings 2/D Straight line on cosi Plant and m&¢hinery 20/0 straight line ot) ¢tsst Fixtures. fittsngs and equipment 20/0 Straighi line on cosi Motor vehicles 20/0 Styaight line on co Taxation The charity is an exempt charity Within the meaning of s¢hedul¢ 3 of the Chtritie5 Act 2011 and is consi(kred to pass the tests to ensure it is exempi from tax on its ¢hariiable activities. Fund a¢couttting Unr¢sirict¢d funds ¢an us¢d in acconknce with th¢ ¢haTitabl¢ obje¢tiY¢s at th¢ diwr¢tion of the irust¢es. Restricted futMLs call only be used for partitular restricted purw5es within the objects of the charity. Restrictions arise when specified by the dtsnor or when funds are raised for particular restricted purposes. Further explanation of the nature alld pury)ose of each fLd is illcluded in the notes to the finaDcial 5tatemellt$. -20- continued...
Drug Safety Researeh Trust Notes to the FirAan¢ial StatemeDts- contilllled for the Year Ellded 31 Decemb¢T 2025 ACCOUNTING POLICIES- contAnued Forelgn eurrencles Assets and liabilities ill foreign currencies are Iranslaied into st¢rliDg at the rates of exchange ruling at the statement of fanCIal position date. Transactions in foreign currencies are translated into sterlin8 at the rat¢ of exchange wling at the date of tsallsaction. Exchange differences are takell into acwut)t in arrivin8 at the operating resulL Pellsloll Costs And other post-retirement benefits The charity operatts a defined contriblltion pension sche]ne. Contributions payable to the ¢harit)es peDSiOll 8ehetlle are charged to the ststement of Financial Activitie5 ill the period to which they relat¢. Don8ted goods The ¢harity does llot receive ally donated goods or gifts in kind. Flnanel41 Instrument5 The charity only holds basic fancial it]strumellts a5 def]ned in FRS 102. The fJnaDcial assets and finaneial liabiliiies of the charity aThl their me&sureTnent basis we as follows.. Financial ass Fiyed asset investments publicly traded fi]nds and shares are basic financial instrnm¢nts and are measured at fair value with Changes in fair value recognÈsed in the StateTneD¢ of Finan¢ial Activities. Trad¢ other debtors are basic financial instruments and ar¢ d¢bt instruments measured at amortised cost as detailed in the debtors note to the5¢ financial statements. Fr¢paynnts and accrued income are not fit)ancial instrnrnents. C&8h at ballk- is cla55ified as a basic financial instrnment and is measured at face value. Financial liabilitie5 Trade creditors and otheT cieditors are basi¢ financial instn]ments, and are measured at amortised cost &8 detailed in the creditors note to these fingn¢ial statements. Ttion and social se¢urity are noi included in thc finallcial instTuinents disclosure d¢fJnition. Accruals and deferred iThcornt is noi deemed to be a financial liability, a5 the cash settlement has already taken place and there is an obligatiim to deliver services rather than cash or another finaijcial instnmient. Other bAlante sbeet items Cash at bank and hand inclEuled cash and short terni highly liquid inve5tment5 with a short mati]rity of three months or less from th6 date of acquisiiion or opening of the deposit or 5iTnilar account. Provisions are recognised wh¢n the Charity has at) obllgation at the tH>Orting dat¢ as a result of a past event whieh it 15 probthle will result in the transfer of economic benefits and the obligation Can be estimated reliably. ProvisioDS aTe measured at the best estimate of the amounts required to Settle the obligation. Where the effect of the time value of money is maierial, the provision is b&%ed on tht present value of those amowits, dis¢ount¢d at the pre-tax di5COLirit rate that reflects the risks $CIfiC to the liability. The unwinding of the di%ount is recognised within interest payabl¢ at)d simil2r charye5. -21- ¢onlinued...
Drug Safety Res¢9r¢h TTll$t Notes to the Fin*n¢i41 Statements- eontinued for the Year Ellded 31 December 2025 DONATIOf4S AND LEGACIES 31112125 Total funds 31112124 Total funds Unr¢5tri¢ted funds Restrl¢ted fndS Dollatiolls 958,187 958,187 704,584 Ir4VESTMENT INCOME 31112n5 Total funds 31112124 Totsl funds Uttre$trict¢d R¢stri¢ted funds funds Gain on dtsposal of investment Listed in¢ollLe Interest ie¢eived 113,084 92,335 51,656 l 13.084 92,335 51,656 41,849 66,907 126,043 257,075 257,075 234,799 OTHER INCOME 31112125 Total funds 31112124 Total fund$ Unrestrlcted funds Restricted funds Other incom¢ 35,665 35,665 233,762 RAISIIYG FUNDS lrtvestment management costs 31112125 Totsl funds 31112124 Total funds Unrestrltted funds Restricted funds Fund mallag¢r costs 24,341 24,341 24,633 CHARITABLE ACTIVITIES COSTS Support costs {5ee not¢ 7) Dlrect Costs Totals Direct Charitable Expenditure 1,450.187 2,572 1.452,759 continued...
Drug Safety ReseAr¢h Trust Note5 to the FiDaDcial StAtements- contlnmed for the Year Ended 31 DeCeber 2025 SUPPORT COSTS Governance Fln#n¢e Totals Other ie50urces expended Direct Clwitable Expenditure 765.871 765.871 2,572 2.572 2,572 765.871 768.443 Support C05t4 included in ihe aboye, are as follows.- 31112125 31112124 Otber resources expended Direet Charitable Expelldlre Total actlvitles Total ctlvities Loss on sale of tangible fixed assets Wages Social security Pen5iOnS Auditors, remuneralio Auditors, remuneration for non audit work Rates and water Insurance Light and heat Telephone and fax pps Sundries Repairs and n)aintellan¢e Staflmedical costs Motor and ttavel expenses Computer costs Subscripiiorts Bank charges Marketing costs Equipjnent hire Depreciation of tangible fixed assets 2,572 2,572 181,354 159,023 105,712 16,090 2220 12,537 24J66 29.605 2.045 1.496 11,152 29,859 5,642 49,140 16,954 47,418 824 30,074 1,852 38,508 181.354 159,023 105,712 I6,(0 2,220 12,537 24,366 29,605 2,(WS 1,496 11.152 29.859 5.642 49,140 16,954 47.418 824 30,074 1,852 38,508 178,021 150,351 97.095 11,720 22,780 26,079 4,612 765 4,642 23,941 8,198 51,932 14,717 62,363 136) 44,208 2,730 31,669 765.871 2,572 768,443 746.924 -23- continued..
Drng Safety Research Trnst Note$ to the Finan¢ial Stat¢m¢nt$- ¢ontinMed for the Year Ended 31 December 2025 AUDITORS, REMUNERATION 31112125 31112124 Fees payable to the charitys auditors for tbe audit of the charity's finan¢ial statements Audiiors, remuneraiTron for llon audit wo 16,090 2,220 11,720 TRUSTEES, REMUNERATION AND BENEFITS Th¢ro were no trust¢es' remuneration OT Qther b¢nefits for the year et)ded 31 December 2025 nor for the year ¢nd¢d 31 Dec¢mber 2024. Trustees, expenses rrust¢es indemnity insurance payable during the year amounted to £8,160 (2024.. £7,844}. Tn]stees expenses during the year aTrLount¢d £1,915 (2024.. £7L) io. srAFF COSTS The ave¥age number of employees during the year was 26 (2024- 26}. The number of ¢mploy¢¢s whose annu21 emoluments were £60,000 or more were.. 2025 2024 £230,001- £31M).000 £II)0,001- £230,000 £70,001- £100,000 £60,001- £70,000 The Éotal remuneration iEJcluding pensions paid to key nllagernent personnel in the year was £265,460 (2024: £266,912). -24 Continued...
Drllg Safety Research Trust Notes tts the Flnan¢i#l StAtemeDts- c•ntlDued for the Year Ended 31 December 2025 ii. TANGIBLE FIXED ASSETS Fixtures and rittittgs Freehold property Plant and acbinery Computer system Totals COST At l JatLuary 2025 A(Idrti(>ns Disposals 941,0(Kl 220,436 32,714 {92,437) 67.857 13.213 57,036 1286,329 45,927 {149,473) 157.0361 At 31 December 2025 941,000 160,713 81.070 1,182.783 DEPRECIATION At l January 2025 Charge foi year Eli1ated on dtsposal 525,500 18,780 177,706 16,621 189,866) 66,383 3.107 57.036 826,625 38,508 {146,902} {57.036) At 31 December 2025 544280 104,461 69,490 718231 NET BOOK VALUE At 31 December 2025 396.720 56,252 11,580 464.552 At 31 December 2024 415,500 42,730 1,474 459,704 The freehold property was last revU¢d otj 20 December 1999 by M¢ssr5 Danie115 HaTison, Chartered Surveyors, on the basis of open market value for currettt use. The freehold land and building5 valualiot) not been updated since 1999. Und¢T the transitional relief provisions ullder FRS 102, this value has been treated as the deemed cost in thes¢ finan¢ial statemellts.The estimated market va]ut per the charity as at the balan¢¢ sheet date, is in excess of £4 million. Comparable historical cost for the land and buildings included at valuation.. 2025 2024 Cost A¢¢llmulated Depreciation At year end 1,487,614 544 280 943 334 1,487.614 525 500 All other tangibl¢ fIxed assets are ated at historical cost less ¢uMulated depreciatioTr. -25- continlle(L..
Drug Safrfy R¢sear¢h Trust Notes to the FSrt#nclal St•tements- continued for the Year Ended 31 DeCeber 2025 12. FIXED ASSET INTrTSTMENTS Listed Investments MARKET VALUE At l January 2025 Additions Disposals Reyaluatious 4,311,066 199,866 151Y),0001 209,474 At 31 Decetnbei 2025 4,220,406 NET BOOKVALUE At 31 Decernber 2025 4,220,406 At 31 Decernber 2024 4,311,066 lThvestm¢nis were fomierly v&lued by ihe Investtnent Fund Managers. Investec Wealth and Investment Limited. but then transferred to Rathbones UK mid year. The asset allocation. including geographical location, of the rtfoliO is set Ollt below.. 2025 2024 UK fjxed income Overseas fixed income UK equities Overseas equities Property Alternative$ C&sh 538,206 167,025 1,348,655 1,544,116 151,104 422,319 48,981 630,462 375,520 781,784 1.953.645 57,575 443,574 68,506 Total 4.220.406 4.311.066 Cost or valuation 31 December 2025 is represented by: Listed investments Valuatiort in 2025 4,220,406 Net additions at ¢ost represent investm¢llt income Teinvested at souw¢ in the Televani fvnds held. InvestnntS were valued by the Investment Fund Managers, Rathbon¢s UK, as at 31 December 2025. -26- continued...
Drug Safety Re5earth Trll5t Note5 to the Fiti#n¢ial Statements- contlnued for the Year Ellded 31 December 2025 13. DEBTORS: AMOUNfs FALLING DUE WITHIN ONE YEAR 31112125 31112124 Trade debtors Other debtors Prepayments and acerned income 262,099 23,665 37,853 228,028 80,000 192,372 323,617 5Th),400 14. CREDITORS: AMOUNtS FALLING DUE WH1 ONE YEAR 31112125 3124 Trade Creditors Taxation and social security Other Creditors 4,751 48,447 21.108 15.491 57,261 8,425 74,306 81,177 Is. MOVEMENT IN FUNDS Net movement in funds At 311J2125 At 111125 Unrestrlcted funds Ullrestticted Fund 6.866,214 {763,790) 6,102,424 Restricted fund$ Restricted Fund 415.500 118,780) 396,720 TOTAL FUNDS 7,281,714 {782,570) 6.499,144 Net movement in furtds, inclu(kd in the above are as follows.. Ineomlng Tesollrces Resources expended Gains and losses Movetnent in funds UDrestri¢ted fund$ Uwestricted Fund 1250,927 (2,224.191) 209,474 1763,790) Restrlcted funds Restricted Fund (18,780) 118,780) TOTAL FUNDS 1250,927 12242,971) 209.474 {782,570} -27- continued...
Drug Safety Research Trn5t Detail¢d Statement of Fin#rtelal Activities for the Year Ended 31 December 2025 31112125 31112124 INCOME AND ENDOWMENTS Don8tloD$ and legacies Donations 958,187 704,584 Investment Income Gain on disposal of tnve5tment Listed income Interest ceiVed 113.084 92,335 51,656 41.849 66.907 126.043 257.075 234,799 Otber income Other income 35.665 233,762 Total Enco1% resources 1,250.927 1.173.145 EXPENDITURE Investment managemeTht eosts Fund manager ¢osts 24,341 24.633 Charitable aetlTr4ties Wages- direct Gencral Practiiioner costs Other direci costs .121.445 49,625 279,117 1,141,466 109,683 455,695 1,450,187 1,706,844 Support eosts Ffnan¢e Loss on sale of tangible fixed assets 2,572 Governance eosts Wages Social sea]rity Pensions Auditors, remuneratiot) AudiÈors' remuneration for non audit work Rates and water Insurance Light and heat Telq)hont and fax pps Sundries Repair5 and maitttenance Carried forward 181,354 159,023 105,712 16,090 2.220 12.537 24.366 29.605 2.045 1,496 11,152 29.859 575.459 178.021 150.351 97,095 11,720 11,137 22,780 26,079 4.6L2 765 4,642 23,941 531,143 This page does not fom] part of the Statutory financial stattmcnts -30-
Drug Safety Research Trust Det•lled StatemeDt of Financial Activities for the Year Ellded 31 December 2025 31112125 31112124
vernaDce costs Brought forward Siaff medical cosÉs Motor and trav¢1 exp¢ns¢s Computcr costs Subscriptions Bank charges Marketing eosts Equipmcnt hire D¢pT¢ciation of tall1¢ fixed #ets 575.459 5,642 49,140 16,954 47.418 824 30.074 1.852 38.508 531,143 8,198 51,932 14,717 62,363 {36} 44.208 2.730 31.669 765,871 746,924 Total r¢$our¢es expended 2.242,971 2,478,401 Net expenditllTe before gains Ios8es 1992.(H4) {1.305256) Netlosses on Investments Net gains I losses on ittvestments 209,474 113,703 Net expenditure {782,570} (1,191,553) ThÈs page does t)ot fomi part of the StatOry financial statements -31-